Ludger Grosse-Hovest

This inventor holds 6 USPTO granted patents and 2 published patent applications, plus 2 CIPO patents and 6 EPO patents. Top assignees: Probiocon Gmbh, Synimmune Gmbh, Baliopharm Ag. Active years: 2015-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ludger Grosse-Hovest. Retrieved from https://idiyas.com/inventor/ludger-grosse-hovest

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 6 (Patent Applications = 2)

% Patents Active = 66.7

CIPO Patents = 2 (Patent Applications = 3)

EPO Patents = 6 (Patent Applications = 7)

Average Co-Inventor Count = 3.1

ph-index = 3

Forward Citations = 59(Granted Patents)

Location History:

Tuebingen, DE (2015 - 2017)
Tübingen, DE (2017 - 2024)

Company Filing History:

4. 1 out of 834,513

Other

patents

Years Active: 2015-2024

Loading Chart...

6 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12048744 - RANKL-specific agent for treating metastatic disease (2024-07-30),

2. 10806786 - RANKL-specific agent for treating metastatic disease (2020-10-20),

3. 10590202 - Recombinant bispecific antibody binding to CD20 and CD95 (2020-03-17),

4. 9718893 - Bispecific antibody molecule (2017-08-01),

5. 9624310 - Methods of using bi-specific antibodies for treating B-cell-mediated autoimmune diseases or auto-reactive B-cells (2017-04-18),

6. 9023996 - Anti-FLT3 antibodies (2015-05-05),

Title: Ludger Grosse-Hovest: Innovator in Cancer Treatment

Introduction

Ludger Grosse-Hovest is a notable inventor based in Tübingen, Germany. He has made significant contributions to the field of cancer treatment, holding a total of 6 patents. His work focuses on innovative approaches to combat metastatic diseases, showcasing his dedication to advancing medical science.

Latest Patents

Among his latest patents is a RANKL-specific agent for treating metastatic disease. This invention provides a RANKL-specific antagonistic agent that recognizes human platelet-expressed receptor activator of nuclear factor kappa-B ligand (pRANKL). It is designed for use in treating cancer patients to prevent or reduce premetastatic lesions in the blood. This groundbreaking work highlights his commitment to improving patient outcomes in oncology.

Career Highlights

Ludger Grosse-Hovest has worked with several companies throughout his career, including Synimmune GmbH and Probiocon GmbH. His experience in these organizations has allowed him to develop and refine his innovative ideas, contributing to the advancement of cancer therapies.

Collaborations

Some of his notable coworkers include Andreas Herrmann and Gundram Jung. Their collaboration has likely played a role in the development of his patents and the overall success of his projects.

Conclusion

Ludger Grosse-Hovest is a prominent figure in the field of cancer treatment, with a focus on innovative solutions to combat metastatic diseases. His contributions through patents and collaborations reflect his commitment to improving healthcare outcomes.

Profile summary based on public USPTO records.